3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
31
Carcinoma, Hepatocellular
30
Neoplasms
19
Carcinoma, Renal Cell
16
Melanoma
10
Carcinoma, Non-Small-Cell Lung
10
Thyroid Neoplasms
9
Endometrial Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
6
Colorectal Neoplasms
5
Triple Negative Breast Neoplasms
4
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Liver Neoplasms
4
Carcinoma, Transitional Cell
4
Uterine Cervical Neoplasms
3
Small Cell Lung Carcinoma
3
Recurrence
3
Lymphoma
3
Esophageal Squamous Cell Carcinoma
3
Esophageal Neoplasms
3
Carcinoma
3
Biliary Tract Neoplasms
3
Stomach Neoplasms
2
Solid Tumors
2
Osteosarcoma
2
Lung Neoplasms
2
Kidney Neoplasms
2
Glioma
2
Diabetes Mellitus, Insulin-Dependent, 12
2
Interventions
pembrolizumab
40
Gemcitabine
37
Cisplatin
28
Carboplatin
17
enfortumab vedotin
15
Nivolumab
15
Mitomycin
14
atezolizumab
13
avelumab
12
Docetaxel
10
vinflunine
9
5-aminolevulinic acid hexyl ester
9
apaziquone
8
Paclitaxel
8
BCG Vaccine
7
durvalumab
6
Fluorouracil
6
Cystectomy
6
sacituzumab govitecan
4
Surgical Procedures, Operative
4
Drug Therapy
4
vofatamab
3
valrubicin
3
tisotumab vedotin
3
erdafitinib
3
cemiplimab
3
belinostat
3
Therapeutic Uses
3
Ramucirumab
3
Cystoscopy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Urinary Bladder Neoplasms
×
lenvatinib
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled